Navigation Links
Newest HIV drugs should be used with FUZEON(R)

Data presented at IAS build a compelling case for FUZEON (enfuvirtide, formerly known as T-20) to be combined with the newest drugs to give patients facing resistance their best chance of achieving undetectable viral load ?the optimal treatment goal for all people living with HIV.

"Undetectable viral load should be the ultimate treatment goal for all triple-class experienced patients. FUZEON combined with the latest drugs now makes this much more achievable," explained Dr Mike Youle the Royal Free Hospital, London. "We are seeing a consistent FUZEON effect with these new drugs and I believe these data must change the way we manage triple class experienced patients facing HIV resistance and failing to reach undetectable viral load."

Studies presented this week show that when FUZEON was given in combination with the novel HIV medication, tipranavir, an impressive 70% of FUZEON naïve patients achieved a ten-fold reduction in their viral load and furthermore they also had double the increase in immune cell count1, compared to patients receiving tipranavir/r without FUZEON.

This adds to the growing body of evidence for the powerful "FUZEON effect" which has been seen across the RESIST 1 & 2, POWER 1 & 2 and TORO 1 & 2 studies, where adding FUZEON was seen to almost double the number of patients reaching undetectable, when combined with one of the latest boosted PIs such as lopinavir/r, tipranavir/r or TMC 114/r.

Doctors underestimate significant "FUZEON effect"

Surprisingly, of the 560 doctors surveyed onsite this week at the IAS conference, three quarters (75%) underestimated the "FUZEON effect" seen in both RESIST2 and POWER3 studies.

Latest data adds to growing Body of Evidence ?Latest Boosted Protease Inhibitors (lopinavir/r, tipranavir/r and TMC 114/r) all work best in combination with FUZEON

RESIST Phase III tipranavir trials
Over 24 weeks, almost double the proportion of patients who received
'"/>

Source:Ketchum


Page: 1 2 3

Related biology news :

1. Molecular machine may lead to new drugs to combat human diseases
2. Researchers identify target for cancer drugs
3. MetaChip provides quick, efficient toxicity screening of potential drugs
4. Newly discovered pathway might help in design of cancer drugs
5. UNC launches study of liver injury caused by drugs
6. Findings have implications for tracking disease, drugs at the molecular level
7. Future diabetes drugs may target new protein interaction
8. UCLA study assesses cost-effectiveness of Hepatitis B drugs
9. Sponges as drugs
10. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
11. FDA approves more generic AIDS drugs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Newest HIV drugs should used with FUZEON

(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/12/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market, announced today ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE SERVICES ... NXT-ID,s position in the emerging "Internet of Things" by ... multiple devices to collaborate with one another to improve ...
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... 35 people in Greece died from a West Nile virus ... new article published in BioMedCentral,s open access journal ... have been responsible for importing and amplifying the deadly virus. ... spread through the bite of infected mosquitoes. Discovered in Uganda ...
... An international research team co-led by a scientist at ... factors behind the third most common form of muscular ... , represent the latest in the team,s series of ... of facioscapulohumeral muscular dystrophy, or FSHD., The team, co-led ...
... schizophrenia is highly genetic in origin, the genes involved in ... few years, researchers have implicated several genes, but it is ... study by researchers at Columbia University Medical Center identifies affected ... the disease. The paper was published today in the ...
Cached Biology News:Did wild birds cause the 2010 deadly West Nile virus outbreak in Greece? 2Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy 2Schizophrenia genetic networks identified; Connection to autism found 2Schizophrenia genetic networks identified; Connection to autism found 3Schizophrenia genetic networks identified; Connection to autism found 4
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape is ... arena, Frost & Sullivan will host its 20 th ... MindXchange , March 8 to 10, at the Hilton San ... This event is a platform for ... to discuss industry disruptions and how to succeed in an ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Already well ... gauging line by expanding its Length Gauge offerings with ... gauges. , Specifically, HEIDENHAIN’s pencil probe-style SPECTO ... force specification. Two new 1Vpp, 12mm stroke length ... force applications. One is a variant with a weak ...
(Date:2/26/2015)... 26, 2015 According to a new ... Market For Transgenic Crops (Corn, Soybean, Cotton and Others), ... Size, Share, Growth, Trends and Forecast, 2013 – 2019,”the ... million in 2012 and is expected to reach USD ... 9.5% from 2013 to 2019. , Demand for ...
(Date:2/26/2015)... THOUSAND OAKS, Calif. , Feb. 26, 2015 /PRNewswire/ ... has achieved Gold Partner status in Oracle PartnerNetwork. In ... Oracle for its commitment to establish Oracle-related knowledge in ... addressing the challenges of joint customers. Originally ... allows researchers to rapidly zoom in and out of ...
Breaking Biology Technology:Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... efficacious for both prophylactic and therapeutic treatmentsVIENNA, ... AMEX: CVM ) announced today ... utilizing its proprietary L.E.A.P.S.(TM) (Ligand Epitope Antigen ... protection against illnesses such as swine influenza. ...
... 28 ITGI Medical, Ltd.,(TASE: ITGI) a company ... tissue covered stents, announced that the US Food,and ... Device),designation to Over and Under(R) and Aneugraft(R) Pericardium ... native coronary arteries and,Saphenous Vein Grafts. , ...
... (NYSE Amex: PIP ), a biodefense company ... today that results from a second Phase II study ... Conference on Vaccine Research, being held in Baltimore, MD, ... National Foundation of Infectious Diseases.David P. Wright, President and ...
Cached Biology Technology:CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7